0 10 Expression expression NN 11 13 of of IN 14 19 c-fos c-fos NN 20 23 and and CC 24 29 c-jun c-jun NN 30 38 proteins protein NNS 39 42 and and CC 43 47 AP-1 ap-1 NN 48 55 binding binding NN 56 64 activity activity NN 65 71 during during IN 72 76 cell cell NN 77 82 cycle cycle NN 83 94 progression progression NN 95 97 of of IN 98 102 HL60 hl60 NN 103 108 cells cell NNS 109 112 and and CC 113 142 phytohemagglutinin-stimulated phytohemagglutinin-stimulated JJ 143 154 lymphocytes lymphocyte NNS 154 155 . . . 157 160 The the DT 161 168 protein protein NN 169 177 products product NNS 178 180 of of IN 181 184 the the DT 185 190 c-fos c-fos NN 191 192 ( ( ( 192 200 p62c-fos p62c-fos NN 200 201 ) ) ) 202 205 and and CC 206 211 c-jun c-jun NN 212 213 ( ( ( 213 221 p39c-jun p39c-jun NN 221 222 ) ) ) 223 228 genes gene NNS 229 232 are be VBP 233 240 members member NNS 241 243 of of IN 244 247 the the DT 248 252 AP-1 ap-1 NN 253 266 transcription transcription NN 267 273 factor factor NN 274 280 family family NN 281 284 and and CC 285 288 are be VBP 289 296 thought think VBN 297 299 to to TO 300 304 play play VB 305 314 important important JJ 315 320 roles role NNS 321 323 in in IN 324 327 the the DT 328 338 regulation regulation NN 339 341 of of IN 342 346 gene gene NN 347 357 expression expression NN 358 364 during during IN 365 368 the the DT 369 373 cell cell NN 374 379 cycle cycle NN 379 380 . . . 381 385 Most most JJS 386 393 studies study NNS 394 396 on on IN 397 400 the the DT 401 411 expression expression NN 412 414 of of IN 415 420 these these DT 421 429 proteins protein NNS 430 432 in in IN 433 441 relation relation NN 442 444 to to TO 445 448 the the DT 449 453 cell cell NN 454 459 cycle cycle NN 460 464 have have VBP 465 469 been be VBN 470 479 performed perform VBN 480 482 at at IN 483 486 the the DT 487 491 mRNA mrna NN 492 497 level level NN 497 498 , , , 499 502 and and CC 503 512 therefore therefore RB 513 515 do do VBP 516 519 not not RB 520 524 give give VB 525 531 direct direct JJ 532 543 information information NN 544 549 about about IN 550 553 the the DT 554 562 presence presence NN 563 565 of of IN 566 569 the the DT 570 578 proteins protein NNS 579 585 during during IN 586 589 the the DT 590 594 cell cell NN 595 600 cycle cycle NN 600 601 . . . 602 604 We we PRP 605 609 have have VBP 610 614 used use VBN 615 622 Western western JJ 623 631 blotting blotting NN 632 634 to to TO 635 646 investigate investigate VB 647 650 the the DT 651 659 presence presence NN 660 662 of of IN 663 668 these these DT 669 677 proteins protein NNS 678 684 during during IN 685 688 the the DT 689 693 cell cell NN 694 700 cycles cycle NNS 701 703 of of IN 704 707 two two CD 708 717 different different JJ 718 726 cellular cellular JJ 727 734 systems system NNS 734 735 : : : 736 737 a a DT 738 750 continuously continuously RB 751 758 growing grow VBG 759 766 myeloid myeloid JJ 767 775 leukemic leukemic JJ 776 780 cell cell NN 781 785 line line NN 785 786 , , , 787 791 HL60 HL60 NNP 791 792 , , , 793 796 and and CC 797 803 normal normal JJ 804 809 cells cell NNS 810 820 stimulated stimulate VBN 821 825 into into IN 826 831 cycle cycle NN 831 832 , , , 833 839 phyto- phyto- NN 840 853 hemagglutinin hemagglutinin NN 854 855 ( ( ( 855 870 PHA)-stimulated pha)-stimulated JJ 871 877 normal normal JJ 878 883 human human JJ 884 894 peripheral peripheral JJ 895 900 blood blood NN 901 912 lymphocytes lymphocyte NNS 913 914 ( ( ( 914 917 PBL PBL NNP 917 918 ) ) ) 918 919 . . . 920 923 The the DT 924 931 binding binding NN 932 940 activity activity NN 941 943 of of IN 944 957 transcription transcription NN 958 964 factor factor NN 965 969 AP-1 ap-1 NN 969 970 , , , 971 976 which which WDT 977 985 consists consist VBZ 986 988 of of IN 989 995 dimers dimer NNS 996 998 of of IN 999 1002 Fos Fos NNP 1003 1006 and and CC 1007 1010 Jun Jun NNP 1011 1017 family family NN 1018 1026 proteins protein NNS 1026 1027 , , , 1028 1031 was be VBD 1032 1036 also also RB 1037 1044 studied study VBN 1045 1050 using use VBG 1051 1052 a a DT 1053 1056 gel gel NN 1057 1062 shift shift NN 1063 1068 assay assay NN 1068 1069 . . . 1070 1072 We we PRP 1073 1078 found find VBD 1079 1086 nuclear nuclear JJ 1087 1095 p62c-fos p62c-fos NN 1095 1096 , , , 1097 1105 p39c-jun p39c-jun NN 1105 1106 , , , 1107 1110 and and CC 1111 1115 AP-1 ap-1 NN 1116 1123 binding binding NN 1124 1132 activity activity NN 1133 1143 throughout throughout IN 1144 1147 the the DT 1148 1152 cell cell NN 1153 1158 cycle cycle NN 1159 1163 both both CC 1164 1166 in in IN 1167 1171 HL60 hl60 NN 1172 1177 cells cell NNS 1178 1181 and and CC 1182 1184 in in IN 1185 1199 PHA-stimulated pha-stimulated JJ 1200 1203 PBL PBL NNP 1203 1204 , , , 1205 1208 and and CC 1209 1211 we we PRP 1212 1221 postulate postulate VBP 1222 1226 that that IN 1227 1232 these these DT 1233 1241 proteins protein NNS 1242 1245 are be VBP 1246 1254 required require VBN 1255 1265 throughout throughout IN 1266 1269 the the DT 1270 1274 cell cell NN 1275 1280 cycle cycle NN 1281 1284 and and CC 1285 1288 not not RB 1289 1300 transiently transiently RB 1301 1303 in in IN 1304 1307 the the DT 1308 1310 G0 g0 NN 1311 1313 to to TO 1314 1316 G1 g1 NN 1317 1327 transition transition NN 1328 1330 as as IN 1331 1339 previous previous JJ 1340 1344 mRNA mrna NN 1345 1352 studies study NNS 1353 1357 have have VBP 1358 1367 indicated indicate VBN 1367 1368 . . . 1369 1371 We we PRP 1372 1384 demonstrated demonstrate VBD 1385 1387 an an DT 1388 1398 uncoupling uncoupling NN 1399 1401 of of IN 1402 1406 AP-1 ap-1 NN 1407 1414 binding binding NN 1415 1423 activity activity NN 1424 1428 from from IN 1429 1437 p62c-fos p62c-fos NN 1437 1438 , , , 1439 1442 and and CC 1443 1451 p39c-jun p39c-jun NN 1452 1456 AP-1 ap-1 NN 1457 1465 activity activity NN 1466 1469 was be VBD 1470 1479 expressed express VBN 1480 1484 more more RBR 1485 1493 strongly strongly RB 1494 1496 in in IN 1497 1500 the the DT 1501 1504 G1- G1- NNP 1505 1508 and and CC 1509 1519 G2/M-phase G2/M-phase NNP 1520 1528 enriched enriched JJ 1529 1536 samples sample NNS 1537 1541 than than IN 1542 1544 in in IN 1545 1548 the the DT 1549 1556 S-phase S-phase NNP 1557 1565 enriched enriched JJ 1566 1573 samples sample NNS 1574 1576 of of IN 1577 1581 HL60 hl60 NN 1582 1587 cells cell NNS 1587 1588 , , , 1589 1594 while while IN 1595 1601 levels level NNS 1602 1604 of of IN 1605 1612 nuclear nuclear JJ 1613 1621 p62c-fos p62c-fos NN 1622 1625 and and CC 1626 1634 p39c-jun p39c-jun NN 1635 1639 were be VBD 1640 1648 constant constant JJ 1648 1649 . . . 1650 1656 Nuclei Nucleus NNP 1657 1659 of of IN 1660 1672 unstimulated unstimulated JJ 1673 1676 PBL pbl NN 1677 1681 from from IN 1682 1691 different different JJ 1692 1698 donors donor NNS 1699 1708 expressed express VBD 1709 1717 p62c-fos p62c-fos NN 1718 1721 and and CC 1722 1730 p39c-jun p39c-jun NN 1730 1731 , , , 1732 1735 but but CC 1736 1740 AP-1 ap-1 NN 1741 1744 was be VBD 1745 1748 not not RB 1749 1757 detected detect VBN 1758 1760 in in IN 1761 1764 the the DT 1765 1773 majority majority NN 1774 1776 of of IN 1777 1784 samples sample NNS 1784 1785 . . . 1786 1795 Following follow VBG 1796 1799 PHA PHA NNP 1800 1811 stimulation stimulation NN 1812 1814 of of IN 1815 1818 PBL PBL NNP 1818 1819 , , , 1820 1823 the the DT 1824 1832 increase increase NN 1833 1835 in in IN 1836 1840 AP-1 ap-1 NN 1841 1849 activity activity NN 1850 1853 was be VBD 1854 1861 delayed delay VBN 1862 1866 with with IN 1867 1874 respect respect NN 1875 1877 to to TO 1878 1881 the the DT 1882 1894 augmentation augmentation NN 1895 1897 of of IN 1898 1906 p39c-jun p39c-jun NN 1907 1917 expression expression NN 1917 1918 . . . 1919 1921 We we PRP 1922 1926 also also RB 1927 1935 observed observe VBD 1936 1940 that that IN 1941 1952 cytoplasmic cytoplasmic JJ 1953 1961 p62c-fos p62c-fos NN 1962 1965 and and CC 1966 1974 p39c-jun p39c-jun NN 1975 1979 were be VBD 1980 1987 present present JJ 1988 1990 in in IN 1991 1995 HL60 hl60 NN 1996 2001 cells cell NNS 2002 2005 and and CC 2006 2020 PHA-stimulated pha-stimulated JJ 2021 2024 PBL pbl NN 2024 2025 . . . 2026 2033 However however RB 2033 2034 , , , 2035 2037 no no DT 2038 2049 cytoplasmic cytoplasmic JJ 2050 2058 p62c-fos p62c-fos NN 2059 2062 was be VBD 2063 2071 detected detect VBN 2072 2074 in in IN 2075 2087 unstimulated unstimulated JJ 2088 2091 PBL PBL NNP 2091 2092 , , , 2093 2101 although although IN 2102 2104 in in IN 2105 2109 some some DT 2110 2115 cases case NNS 2116 2127 cytoplasmic cytoplasmic JJ 2128 2136 p39c-jun p39c-jun NN 2137 2140 was be VBD 2141 2149 detected detect VBN 2149 2150 , , , 2151 2161 suggesting suggest VBG 2162 2166 that that IN 2167 2178 subcellular subcellular JJ 2179 2199 compartmentalization compartmentalization NN 2200 2202 of of IN 2203 2208 these these DT 2209 2220 proteinsmay proteinsmay NN 2221 2226 occur occur VBP 2227 2232 under under IN 2233 2240 certain certain JJ 2241 2254 circumstances circumstance NNS 2254 2255 . . .